LUPIN Ltd - Positive Outlook Backed by the Launch of Niche Products
The company’s sales were up 28.6% YoY at Rs 4,330 Cr, and the growth was majorily led by its India business (+9.8% YoY), EMEA (+19.6% YoY)
265 Views
Pick of the Week: Lupin Ltd - 10 JULY 2023
Lupin is an innovation-led transnational pharmaceutical company. It, develops and commercializes a wide range of branded and generic formulations,...
248 Views
Lupin - GSpiriva Approval a Overall Turnaround in The Business
Lupin has received approval from generic version of Spiriva HandiHaler (Tiotropium Bromide Inhalation Powder) from USFDA in the US Market.
271 Views
LUPIN Ltd - Margins Improvement to Be The Key to Future Performance
US sales got impacted due to the lack of new launches and seasonality, gSupreb has strong volume growth, and Alubetrol has a stable market share of...
350 Views
Pharma Sector: Q2FY24 Review
In Q2FY24, the Pharma Coverage universe posted robust revenue growth of 14.3%/1.7% YoY/QoQ on account of volume rampup, new launches (especially...
292 Views